Contineum Therapeutics is expected to report a Q3 2026 loss of $0.45 per share on revenue of $5.65 million, with the stock currently trading near $8.35 against an average analyst target of $22.14.
Investors are primarily focused on clinical execution and enrollment updates for the Phase 2 PROPEL-IPF trial of PIPE-791, which is now the company's core valuation driver.
This earnings report follows significant clinical setbacks for PIPE-307, which recently failed to meet primary endpoints in Phase 2 trials for both multiple sclerosis and major depressive disorder.
In response, the company has streamlined its workforce to preserve a cash runway of approximately $246 million, which is projected to fund operations through mid-2029.